At STgen Bio, we place the highest priority on the well-being and health of patients and are committed to producing biopharmaceuticals of exceptional quality that instill trust and assurance.

I'm Kyung-Eun Choi, the CEO of STgen Bio.

STgen Bio, started as a joint venture in 2015 between Dong-A Socio Holdings and Japan's Meiji Seika Pharma under the name, DM Bio. Within just four years of our establishment as a biopharmaceutical manufacturer, we successfully passed the Japan PMDA’s GMP compliance inspection and our manufactured products are currently being sold in the Japanese market.

As the company governance unified under Dong-A Socio Holdings in 2021, STgen Bio is preparing for GMP inspections from US and European health authorities in schedule with the development timeline of the Stelara biosimilar, DMB-3115, a joint project of Dong-A ST and Meiji Seika Pharma, by upgrading the company’s manufacturing and quality control systems to cGMP standards.

Based on the experience and know-hows gained through Dong-A Socio Group's biopharmaceutical manufacturing and its entry into the global market, STgen Bio is aiming to contribute to the expansion of the K-Bio global market through cooperation with the leading domestic bio-ventures and companies.

To achieve this, we will establish a manufacturing and quality management system that can promptly respond to the changes in global health regulations and expansion of production facilities to build competitiveness as a global CMO that attends to our client’s various needs

STgen Bio is continuously growing each and every day. We strive to be a company where all employees can grow and develop along with the company.

Thank you.

Kyung-Eun Choi, CEO of STgen Bio

I am curious about the atmosphere of the company.

Although STgen Bio is a little different from the meaning of freedom, I believe that an environment where challenges can be created is created as each employee acts with confidence and such aspects lead to personal growth. Due to the nature of the cGMP-based work process of biopharmaceutical production, anything is not immediately possible, but I would like to support the employees so that their challenge of ‘what I want to do’ can be realized and employees can shine.